252 related articles for article (PubMed ID: 9759701)
1. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
2. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
Monti S; Sciarra F; Adamo MV; Toscano V; Trotta MC; Martini C; Lanzara S; Silverio FD
J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
[TBL] [Abstract][Full Text] [Related]
3. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue.
Sciarra F; Monti S; Adamo MV; Palma E; Toscano V; d'Eramo G; di Silverio F
Urol Res; 1995; 23(6):387-90. PubMed ID: 8788277
[TBL] [Abstract][Full Text] [Related]
4. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
Plosker GL; Brogden RN
Drugs Aging; 1996 Nov; 9(5):379-95. PubMed ID: 8922564
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
6. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
Vacherot F; Azzouz M; Gil-Diez-De-Medina S; Colombel M; De La Taille A; Lefrère Belda MA; Abbou CC; Raynaud JP; Chopin DK
Prostate; 2000 Nov; 45(3):259-66. PubMed ID: 11074529
[TBL] [Abstract][Full Text] [Related]
9. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
10. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
Buonocore D; Verri M; Cattaneo L; Arnica S; Ghitti M; Dossena M
Arch Ital Urol Androl; 2018 Sep; 90(3):199-202. PubMed ID: 30362688
[TBL] [Abstract][Full Text] [Related]
11. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Bayne CW; Donnelly F; Ross M; Habib FK
Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
[TBL] [Abstract][Full Text] [Related]
12. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Habib FK; Ross M; Ho CK; Lyons V; Chapman K
Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
[TBL] [Abstract][Full Text] [Related]
13. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
14. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
15. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
Monti S; Di Silverio F; Toscano V; Martini C; Lanzara S; Varasano PA; Sciarra F
J Androl; 1998; 19(4):428-33. PubMed ID: 9733145
[TBL] [Abstract][Full Text] [Related]
16. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
Boyle P; Robertson C; Lowe F; Roehrborn C
BJU Int; 2004 Apr; 93(6):751-6. PubMed ID: 15049985
[TBL] [Abstract][Full Text] [Related]
17. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP;
Prog Urol; 2002 Jun; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
[TBL] [Abstract][Full Text] [Related]
19. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens.
Levin RM; Das AK
Urol Res; 2000 Jun; 28(3):201-9. PubMed ID: 10929430
[TBL] [Abstract][Full Text] [Related]
20. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
Paubert-Braquet M; Cousse H; Raynaud JP; Mencia-Huerta JM; Braquet P
Eur Urol; 1998; 33(3):340-7. PubMed ID: 9555564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
